Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Pharmacokinetics of CAMPATH-1H in BMT patients.
Intermittent self-catheterisation in MS.
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis.
Change in the clinical development program for laquinimod
Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case--control ultrasound study.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Biogen Idec completes purchase of full rights and control of Tysabri®
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Glatiramer acetate in the treatment of multiple sclerosis
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
The interplay between the intestinal microbiota and the brain.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.

Pages